EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pneumococcal Serotype Distribution and Coverage of Existing and Pipeline Pneumococcal Vaccines

Laura M King iD, Kristin L Andrejko, Miwako Kobayashi iD, Wei Xing iD, Adam L Cohen iD, Wesley H Self iD, J Jackson Resser iD, Cynthia G Whitney iD, Adrienne Baughman, Mai Kio, Carlos G Grijalva, Jessica Traenkner und 2 weitere

The Journal of Infectious Diseases · 15.10.2025 · 232 (4) · e609-e620

DOI: 10.1093/infdis/jiaf376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 22.07.2025. Verfasst von Laura M King und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, University of California, Berkeley, Berkeley, California, USA. Hauptthemen laut MEDLINE: Pneumococcal Vaccines, Streptococcus pneumoniae, Pneumococcal Infections. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, CDC HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Next-generation pneumococcal conjugate vaccines (PCVs) target an expanding array of serotype antigens. We assessed the proportions of invasive pneumococcal disease (IPD) and pneumococcal acute respiratory infections (ARIs) caused by serotypes targeted by existing and pipeline PCVs, and the annual United States pneumococcal disease burdens potentially preventable by these products.

Methods

We estimated serotype distribution and proportions of pneumococcal ARIs (acute otitis media [AOM; children only], sinusitis, nonbacteremic pneumonia) and IPD attributable to serotypes targeted by each PCV using Markov chain Monte Carlo approaches incorporating data from epidemiological studies and Active Bacterial Core surveillance. We then estimated annual numbers of outpatient-managed ARIs, nonbacteremic pneumonia hospitalizations, and IPD cases potentially preventable by PCVs by multiplying disease incidence rates by PCV-targeted disease proportions and vaccine effectiveness estimates.

Results

In children, PCV15, PCV20, PCV24, PCV25, and PCV31 serotypes account for 16% (95% confidence interval, 15%–17%), 31% (30%–32%), 34% (32%–35%), 43% (42%–44%), and 68% (67%–69%) of pneumococcal AOM, respectively. In adults, PCV15, PCV20, PCV21, PCV24, PCV25, and PCV31 serotypes account for 43% (38%–47%), 52% (47%–57%), 69% (64%–73%), 65% (61%–70%), 62% (57%–67%), and 87% (83%–90%) of pneumococcal nonbacteremic pneumonia. For IPD, 42%–85% of pediatric and 42%–94% of adult cases were due to PCV-targeted serotypes. PCV-preventable burdens encompassed 270 000–3 300 000 outpatient-managed ARIs, 2000–17 000 pneumonia hospitalizations, and 3000–14 000 IPD cases annually.

Conclusions

Across pneumococcal conditions, coverage and preventable burdens were lowest for PCV15 and highest for PCV31, with PCV21 also targeting sizeable burdens of adult disease. Comparative estimates of preventable disease burden may inform future policy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pneumococcal VaccinesStreptococcus pneumoniaePneumococcal InfectionsHumansSerogroupChild, PreschoolInfantUnited StatesChildVaccines, ConjugateAdolescentAdultOtitis MediaMiddle AgedAgedMaleRespiratory Tract InfectionsYoung AdultFemaleHospitalizationIncidence

Stichwörter der Autor:innen

Streptococcus pneumoniaeacute otitis mediainvasive pneumococcal diseasepneumococcal conjugate vaccinespneumonia

Substanzen

Pneumococcal VaccinesVaccines, Conjugate

Autor:innen und Institutionen

  • School of Public Health, University of California, Berkeley, Berkeley, California, USA.
  • Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
  • Department of Medicine, Emory University, Atlanta, Georgia, USA.

ORCID-Profile: Laura M King, Miwako Kobayashi, Wei Xing, Adam L Cohen, Wesley H Self, J Jackson Resser, Cynthia G Whitney, Nadine Rouphael

Förderung

  • NIAID NIH HHS
  • CDC HHS
  • NIH HHS
  • Centers for Disease Control and Prevention
  • National Institutes of Health

Zitieren

APA

King, L. M., Andrejko, K. L., Kobayashi, M., Xing, W., Cohen, A. L., Self, W. H., Resser, J. J., Whitney, C. G., Baughman, A., Kio, M., Grijalva, C. G., Traenkner, J., Rouphael, N., & Lewnard, J. A. (2025). Pneumococcal Serotype Distribution and Coverage of Existing and Pipeline Pneumococcal Vaccines. The Journal of Infectious Diseases, 232(4), e609-e620. https://doi.org/10.1093/infdis/jiaf376

Vancouver

King LM, Andrejko KL, Kobayashi M, Xing W, Cohen AL, Self WH, et al. Pneumococcal Serotype Distribution and Coverage of Existing and Pipeline Pneumococcal Vaccines. The Journal of Infectious Diseases. 2025;232(4):e609-e620. doi:10.1093/infdis/jiaf376

BibTeX
@article{King2025,
  author = {King, Laura M and Andrejko, Kristin L and Kobayashi, Miwako and Xing, Wei and Cohen, Adam L and Self, Wesley H and Resser, J Jackson and Whitney, Cynthia G and Baughman, Adrienne and Kio, Mai and Grijalva, Carlos G and Traenkner, Jessica and Rouphael, Nadine and Lewnard, Joseph A},
  title = {Pneumococcal Serotype Distribution and Coverage of Existing and Pipeline Pneumococcal Vaccines},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  volume = {232},
  number = {4},
  pages = {e609--e620},
  doi = {10.1093/infdis/jiaf376}
}
Kostenlos starten →